2 weeks Ago By ABMN Staff
Genprex ( NASDAQ:GNPX – Get Free Report ) and Sonnet BioTherapeutics ( NASDAQ:SONN – Get Free Report ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Analyst Ratings This is a breakdown of recent recommendations and price targets for Genprex and Sonnet BioTherapeutics, as provided by MarketBeat. Genprex currently has a consensus target price of $10.
00, indicating a potential upside of 2,595.42%. Sonnet BioTherapeutics has a consensus target price of $30.
00, indicating a potential upside of 4,127.73%. Given Sonnet BioTherapeutics’ higher probable upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Genprex.
Risk & Volatility Institutional & Insider Ownership 14.1% of Genprex shares are held by institutional investors. Comparatively, 9.
4% of Sonnet BioTherapeutics shares are held by institutional investors. 11.5% of Genprex shares are held by company insiders.
Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability This table compares Genprex and Sonnet BioTherapeutics’ net margins, return on equity and return on assets. Earnings & Valuation This table compares Genprex and Sonnet BioTherapeutics”s top-line revenue, earnings per share and valuation. Sonnet BioTherapeutics has higher revenue and earnings than Genprex.
Summary Sonnet BioTherapeutics beats Genprex on 6 of the 10 factors compared between the two stocks. About Genprex ( Get Free Report ) Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States.
The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. About Sonnet BioTherapeutics ( Get Free Report ) Sonnet BioTherapeutics Holdings, Inc.
, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.
The company is headquartered in Princeton, New Jersey. Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter .
.
